Patient demographics at baseline (N = 321)
| . | Values . |
|---|---|
| Median age, y (range) | 58 (21-85) |
| Median duration of CML, mo (range) | 58 (5-275) |
| Median duration of prior imatinib therapy, mo (range) | 32 (< 1 to 94) |
| Imatinib resistant | 39 (2-94) |
| Imatinib intolerant | 14 (< 1 to 64) |
| Active disease before therapy, n (%) | 207 (64) |
| Imatinib resistant/intolerant (%) | 70/30 |
| Prior imatinib ≥ 12 mo, n (%) | 266 (83) |
| Imatinib resistant, n/N (%) | 215/226 (95) |
| Imatinib intolerant, n/N (%) | 51/94* (54) |
| Prior highest imatinib dose ≥ 600 mg/d, n (%) | 232 (72) |
| Imatinib resistant, n/N (%) | 201/226 (89) |
| Imatinib intolerant, n/N (%) | 31/94 (33) |
| Other prior therapy | |
| Hydroxyurea, n (%) | 266 (83) |
| Interferon, n (%) | 187 (58) |
| Cytarabine, n (%) | 78 (24) |
| Response at baseline, n (%) | |
| Complete hematologic response | 114 (36) |
| Major cytogenetic response | 35 (11) |
| Complete cytogenetic response | 10 (3) |
| . | Values . |
|---|---|
| Median age, y (range) | 58 (21-85) |
| Median duration of CML, mo (range) | 58 (5-275) |
| Median duration of prior imatinib therapy, mo (range) | 32 (< 1 to 94) |
| Imatinib resistant | 39 (2-94) |
| Imatinib intolerant | 14 (< 1 to 64) |
| Active disease before therapy, n (%) | 207 (64) |
| Imatinib resistant/intolerant (%) | 70/30 |
| Prior imatinib ≥ 12 mo, n (%) | 266 (83) |
| Imatinib resistant, n/N (%) | 215/226 (95) |
| Imatinib intolerant, n/N (%) | 51/94* (54) |
| Prior highest imatinib dose ≥ 600 mg/d, n (%) | 232 (72) |
| Imatinib resistant, n/N (%) | 201/226 (89) |
| Imatinib intolerant, n/N (%) | 31/94 (33) |
| Other prior therapy | |
| Hydroxyurea, n (%) | 266 (83) |
| Interferon, n (%) | 187 (58) |
| Cytarabine, n (%) | 78 (24) |
| Response at baseline, n (%) | |
| Complete hematologic response | 114 (36) |
| Major cytogenetic response | 35 (11) |
| Complete cytogenetic response | 10 (3) |
CML indicates chronic myeloid leukemia; active disease refers to patients not in complete hematologic response at the time of study entry.
Imatinib dosing information was missing for 1 patient.